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Michel S. Makaroun, MD, Pittsburgh, PaMembers and Guests,
I am deeply honored to have served as the 33rd presi-
dent of the Society for Clinical Vascular Surgery (SCVS)
this past year and truly humbled to be now listed among
a group of distinguished surgeons who led this society to
its current prominence. The annual meeting of the society
has been one I always looked forward to attend, since I
joined the society in 1989 at the urging of one of my
mentors, trusted friend, and colleague, David Steed. In
his words: “The SCVS is the best meeting of the year:
Excellent papers, relaxed collegial atmosphere, free time
to enjoy friends and family, and it does not hurt that it
rotates between Palm Springs and Florida in March,.
especially when you live in Pittsburgh!” “You will make
great friends, learn a lot and meet some wonderful peo-
ple. and you will learn to enjoy golf.” Except for the
last prediction, he was right on target. Although I had
attended brieﬂy an earlier meeting, I ﬁrst traveled to
Palm Desert for the whole symposium in 1990. I still
remember arriving on a Wednesday afternoon just before
a welcome reception scheduled at 6:30 PM. As I was asking
for directions to the patio where the reception was taking
place, a distinguished gentleman offered to walk me there.
It was the ﬁrst time I met “Herb” Dardik in person, and I
marveled at having the secretary treasurer of the Society,
who had been the president in 1985, take the time to
walk “me” to the reception. He managed to quickly put
me at ease, introduce me to several attendees, and inquire
about his friend Stanley Hirsch in Pittsburgh. I quickly
realized this was to be a different kind of society meetingthe UPMC Heart and Vascular Institute and the Division of Vascular
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://dx.doi.org/10.1016/j.jvs.2013.03.003that I will truly enjoy. I have never missed a meeting since,
and I encourage most of the young surgeons and trainees
in the audience to follow suit.
It was not simply the collegial laid-back tempo that was
attractive but also a scientiﬁc program that truly anticipated
the future needs of practicing vascular surgeons. The
opening session that year included talks on endovascular
training for the vascular surgeon, angioscopy, angioplasty,
atherectomy, stents, and lytic therapy, topics ignored by
the more traditional vascular societies at the time. Both
Thursday and Friday afternoons included workshops on
a variety of endovascular techniques for us non-golfers.
By the end of the session with Tom Fogarty, I knew where
the future of our specialty lies. The meeting that year also
featured talks by other household names including Toshio
Inahara, John Porter, Larry Hollier, John Bergan, and
Wesley Moore, and our ﬁrst international guest speaker,
Mr Eastcott, just to name a few. As our society has grown
and our meeting has matured through the efforts of several
of our presidents and members, I am thrilled that the SCVS
has managed to maintain its casual relaxed atmosphere,
despite adding several new dimensions to its offerings.
The tradition of being at the forefront of endovascular
training was resumed, after a short hiatus, through the
persistent efforts of one of our visionary presidents, Kim
Hodgson, who, in addition, succeeded in attaching
a fellows program to our meeting. This has since grown
to include an incoming fellows program and a young
vascular surgeons program, highlighting the commitment
of our society to the education and support of our young
colleagues. Another of our presidents, Alan Lumsden,
developed this tilt further by championing simulation
training and the very popular Top Gun competition. He
also started our yearly educational exchange with the
Society for Vascular Medicine, emphasizing the need for
a more complete education in vascular disease. Another
strong advocate of the complete modern vascular surgeon,
Enrico Ascher, the president who is never short on ideas for
new initiatives, seized on the rich tradition of the SCVS in
international exchange and developed the ﬁrst international
symposium at our 2003 meeting, with Frans Moll, Giorgio
Biasi, Jose Nasciamento Silva, and Pedro Puech-Leao. I
had the distinct pleasure over the last several years to shep-
herd that tradition along, organizing our international
guest program to enrich our knowledge and understanding
of the practice of vascular surgery beyond our borders.239
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tional visitors, distinguished visiting professors, and
Hume lecturers for taking the time to be with us, including
our guests this year, PierGiorgio Cao, Nick Cheshire,
Christos Liapis, and Richard Cambria.
Standing in front of you today culminates my long love
affair with this Society. After serving for 3 years on the
Program Committee, I was approached in 2003 by then
president Ascher to serve a few more years on the council.
Nine years later, I am delivering this presidential address to
you. It certainly is a far cry from my days as an international
medical graduate and surgical resident in Beirut trying to
land a training position in the U.S. My 89-year-old mother
may be the only person alive to believe that serving as your
president was preordained by my brilliant intellect and
untold talent. Most of you know better, and for the few
who do not, I have 17 partners, 18 residents, 1 wife, 2 chil-
dren, and several secretaries and nurses who would be
willing to set you straight.
Presidential addresses come in all sort of ﬂavors. They
usually carry a serious message to the audience, describe
new initiatives, or address a particular problem the member-
ship may be facing in the immediate future. The last few at
the SCVS addressed “Pay for performance” and quality of
care by Tony Sidawy, academic or private practice by Bill
Brown, the impact of immigrants on medical leadership by
Keith Calligaro, the retraining of the vascular workforce by
Alan Lumsden, and the evolution of vascular surgery by
George “Mickey” Meier. Last year, Joann Lohr, the ﬁrst
woman to lead a national vascular surgery society in the
U.S., delivered an impassioned and heartfelt plea advocating
patients’ rights and championing outcomemeasurements to
guide our clinical decisions, a reminder of the ethical and
moral underpinnings of our profession.
I hate to disappoint, but I do not have a far-reaching
message for you today and will be mostly sharing my
thoughts about two fairly random events of interest that
happen to coincide with our meeting this year: Sunshine
Week and Medical Student Match day.
I have also decided to strike a personal note in this
address today, as I reﬂect on the career that landed me
on this podium today, to illustrate the two issues at hand
and the conﬂicting emotions they provoke.It was the best of times, it was the worst of times,
it was the age of wisdom, it was the age of foolishness,
it was the epoch of belief, it was the epoch of incredulity,
it was the season of Light, it was the season of Darkness,
it was the spring of hope, it was the winter of despair,
we had everything before us, we had nothing before usI am sure you all recognize the opening lines from “A
Tale of Two Cities,” one of the most famous works in the
history of ﬁctional literature, an opening that constantly
rings true nearly 2 centuries after it was written. The two
cities in question were London and Paris in the late 18thcentury, suffering from all the social ills leading up to the
French Revolution, but these may as well have been any
two cities or state of affairs during more modern times.
The quote endures, as it illustrates mostly the ambivalent
feelings most of us have toward the major shifts
surrounding us, be it revolutions and wars that are over-
throwing governments and regimes around the world,
economic calamities that are straining the ﬁnancial order,
or changes in our profession that generate both anxiety
and opportunity, new technology we have to adapt to at
home and at work, and regulations intended to improve
our health care system but occasionally adversely affect
our daily lives.
These are indeed the best of times in vascular surgery,
which has become a vibrant specialty covering the entire
medical, surgical, and interventional management of
vascular disease. We developed a measure of independence
over our destiny with the formation of a Vascular Surgery
Board and new training paradigms. We embraced new
technology, providing the needed leadership in the appro-
priate application of less invasive techniques. We espoused
the push for quality measures that should distinguish us
from others in the ﬁeld. Our value to our hospitals and
colleagues has increased, making vascular surgery one of
the most difﬁcult specialties to recruit for, increasing our
incomes and status in the medical community in the
process.
It is also the worst of times in vascular surgery with our
position as the dominant specialty in vascular care, chal-
lenged by many others, with our patients receiving conﬂict-
ing advice from other specialists who view any vascular
lesion as the nail for the only hammer they have, and
with insurance and government threatening our practices
with drastic cuts and restrictions.PHYSICIAN PAYMENT SUNSHINE ACT
Today is the Fifth Freedom of Information day as part
of the celebration of “Sunshine Week,” which was started
7 years ago by the American Society of News editors. It
celebrates 45 years of the Freedom of Information Act,
which was supposed to shine the sun on secret and poten-
tially corrupt government practices. This year also marks
the implementation of the Physician Payment Sunshine
Act, intended to do the same for our relationships with
industry. This leads me to the ﬁrst topic I would like to
comment on.
Advances in vascular surgery, more than other special-
ties, have become intertwined with the introduction of new
technology and devices, developed through a close collab-
oration between surgeons, innovators, and engineers, to
minimize our invasive footprint and improve patient
outcomes. The close daily interaction of our membership
with industry personnel has become commonplace as the
offerings of new devices multiply daily, and practical tips
about their use are residing more and more with the
vendors. As I reﬂect on my career, collaboration with
industry was very rewarding professionally, affording me
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tively early.
Like many events in life, my initial involvement started
randomly as I was wandering aimlessly among the exhibits
of the Society for Vascular Surgery annual meeting in 1993
and stumbled on a small booth in a far corner without any
displays except for a sign reading: “EndoVascular Technol-
ogies, Inc.” That day I met Lori Adels, a PhD in charge of
regulatory affairs at the start-up company, EndoVascular
Technologies, Inc, who was helping plan the ﬁrst regula-
tory trial of an endograft in the U.S. Over the next
30 minutes, she introduced me to the device, a tube of
polyester with hooks on both ends, and their plans for
a randomized study against open repair. I left with a site
evaluation form and a lot of excitement and anticipation.
Back in Pittsburgh, I failed to convincemy seniors of the
wisdom of applying to join the study, so I applied on my
own, for a site at the VA hospital where I was the sole
vascular surgeon at the time. Needless to say, I was turned
down. It took me 18 more months of trying, until low
recruitment and a change of heart by my seniors ﬁnally
allowed me to enter the trial as an investigator and having
Pittsburgh as a site. Over the next 2 decades, I was blessed
with a fruitful and rewarding interaction with our industry
partners that expanded my horizons personally and profes-
sionally and brought me in contact with amazingly bright
and resourceful engineers who always seem to have a solu-
tion for technical problems we were having clinically. I
met numerous like-minded vascular surgeons from all
corners of the world who enriched my life and provided
me with a cherished insight into the various ways of
delivering health care to our patients worldwide. I witnessed
ﬁrsthand the dramatic evolution of our treatments and
the remarkable salutary effect of technology on patient
outcomes. I was provided the opportunity to participate in
the training of countless colleagues into the emerging endo-
vascular ﬁeld, and for that, I will always be grateful. I made
lifelong friends that I stay in touchwith long after our profes-
sional paths diverged. Although I did experience one or two
inappropriate advances, offers, and requests that I was quick
to dismiss, my interaction with my industry colleagues has
almost always been very professional and focused on
improving products, collecting complete data, and reporting
accurate results. I truly believe that this close professional
working relationship has made me a better physician and
a better surgeon in the service of my patients.
We are currently witnessing, however, many changes
that will alter the way we interact with industry. We
welcome these changes with relief and hope they will end
unsavory and excessive practices that blemished our public
image but also with apprehension they may have unex-
pected consequences. If I sound ambivalent about what
is happening, you are correct: I am. The changes are the
inevitable consequence of many reports that have emerged
over the last few years, focusing on the dark side of
marketing to doctors and the insidious inﬂuence of ﬁnan-
cial enticements paid to physicians, on clinical decision
making. Sensational headlines have alleged widespreadcorruption, oversized payments, inappropriate gifts, and
outright bribes to promote the excessive use of drugs and
devices.
To illustrate the scope of the problem, I will only
provide a couple of examples.
Although AdvaMed (as did PhRMA) developed a code
of ethics in 2003, strengthened in 2009, some excesses
continued.1 In September 2007, ﬁve orthopedic manufac-
turers executed deferred prosecution agreements (DPA)
with the U.S. Attorney’s ofﬁce.2 Under the settlements,
the companies agreed to pay $311 million to settle govern-
ment claims under the anti-kickback statute. As part of the
agreement, the companies started reporting payments on
their websites. A review of these disclosures in 2008, after
the settlement, notes that 526 orthopedic surgeons
received 568 payments totaling more than $228 million.
Twenty-ﬁve percent of the recipients had published less
than two papers, making it less likely to claim involvement
in research. Witness this headline from Pulitzer Prize
winner Pro Publica: “Docs on Pharma payroll have blem-
ished records, limited credentials.”3 It does not help that
fraud ﬁnes for pharmaceutical giants alone totaled $8
billion over the last decade.4 There should be no surprise
a new bill (HR675-Act of 2011) was introduced last year
in Congress to add more bite in the form of exclusion
from participation in any federal health program for sanc-
tioned entities.5 Industry reportedly spent $200 million
in 2011 lobbying Congress against the proposed
legislation.
In another well-publicized case that resulted in indict-
ments and a Senate Committee on Finance hearing in
December of 2010, a cardiologist at St Joseph’s Hospital
in Baltimore was accused of placing 585 coronary stents
that were not indicated over a 2-year period.6 You may
blame our fee-for-service system that encourages some
overuse of high-paying interventions, especially by a few
unscrupulous physicians, but in this case, both the hospital
and the stent manufacturer were ensnared in the contro-
versy, the hospital for paying kickbacks and the company
for inappropriate inducements in consulting payments.
An executive at the company congratulated the cardiologist
for using 30 stents in 1 day, and a representative paid for
a celebration barbecue dinner 2 days later at the cardiolo-
gist’s home. After the physician was unable to practice in
Baltimore, the company still hired him as a consultant to
thank him for support over the years.
These cases are not unique by far, as dozens of other
alleged improprieties have surfaced all over the country
and the world, involving all specialties and almost all major
drug and device companies. Although some payments
are clearly and completely legitimate, it would be futile
to deny that some industry spending on physicians is inap-
propriate and can lead an independent observer to
conclude that an incestuous relationship exists, or at least
is likely to exist, between the two. The multitude of cases,
molded by the sensationalism of media reporting and the
near instantaneous dissemination of information online,
have resulted in a crisis of public conﬁdence in industry
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you: “Crook alert!! Drug and medical device companies
are bribing our doctors and exerting undue inﬂuence on
research.”7 “What are these doctors hiding from us?” is
the caption that accompanies a picture of presumably
four physicians in surgical garb and face masks. “Is your
doctor on Big Pharma’s payroll?”8 I am sure you have
seen some of these and summarily dismissed them as iso-
lated instances blown out of proportion. I urge you not
to, as our patients’ conﬁdence is our most valued currency,
and we must protect it at any cost. The inevitable outcome
of these reports has been the promulgation of several poli-
cies by hospitals, medical schools, professional societies,
industry trade associations (AdvaMed and PhRMA), and
the government aiming to regulate physician industry
interaction, but the worst outcome by far will be a gradual
erosion of trust between patient and physician.
The new policies and regulations are changing the
business-as-usual attitude that marked our relationships
with industry, most of it for the better, curbing abuses
and inappropriate behavior that always made me feel
uncomfortable even when not directed at me, but unfortu-
nately, some of it for the worse, limiting some productive
interactions that helped provide new and innovative treat-
ment modalities. For example, I am no longer allowed to
host sponsored training programs, as they are considered
promotional activities under our new institutional policy.9
If I consult on a device development or even help write
a study protocol, I am no longer allowed to be the local
investigator. We always declared outside income to our
institution and had our contracts approved before we
signed them, but under our new policy, some clauses and
thresholds trigger several levels of review that almost always
dooms them. Although I offered on many occasions to
consult without pay in areas that particularly interest me,
our industry partners would not accept that based on their
legal counsel. Offering the monetary payment to the insti-
tution instead of the individual is opposed by ours as it
apparently shifts the conﬂict to the institution, which is
even less desirable.
Our policies are certainly not unique, as several major
institutions and the Association for American Medical
Colleges have adopted similar stances. A scorecard was
developed by the American Medical Student Association
and the Pew Prescription Project in 2006 to evaluate
Conﬂict of Interest Policies of U.S. Medical Schools. In
its fourth year in 2010, the scorecard project assigned
a score of A or B to the policies of 79 of 152 medical
schools (52%), compared with 45 the year before.10 Nine-
teen schools, including the University of Pittsburgh
Medical Center, received an A grade. Many universities
have completely outlawed any payments, food, gifts, or
anything of value, and in the case of the University of
Michigan, any support for Continuing Medical Education
(CME) activities.11 Several states, most notably Massachu-
setts, Vermont, and Minnesota, have reporting statutes and
restrictions that involve a wide variety of relationships.
Although we all applaud the proper deﬁnition ofboundaries that is long overdue, I am afraid an unexpected
result will be fewer of the fruitful interactions I had with
industry over the years and less involvement of physicians
in device development, which, contrary to drug innova-
tions, relies heavily on user input.
We are witnessing this year a new federal regulatory
requirement for transparency that is being implemented
as part of the Patient Protection and Affordable Care Act
otherwise known as Health Care Reform. Industry is
supposed to have started collecting data on January 1 of
this year, with a mandate to report on January 1, 2013
to the Centers for Medicare and Medicaid Services
(CMS) any payment or transfer of value over $10, I repeat,
$10 in 2012. As of 2008, the act had the public support of
19 consumer and patient groups, 7 provider organizations,
and 21 professional medical associations, as well as
AdvaMed, PhRMA, Medtronic, and Eli Lilly. Implementa-
tion is being slightly delayed, as CMS was late in issuing the
proposed regulations in the Federal Register on December
19, 2011. Comments from interested parties were trans-
mitted to CMS on February 17, 2012.
While none of us would ever quibble with the need for
transparency and the elimination of true and apparent
conﬂict of interest between the profession and our industry
partners, the application of the law as written and the
added interpretations by CMS will have an added effect
on the conduct of research for new devices and drugs
and the way CME is provided in the United States. The
data will be available on a searchable website. If you want
a preview, you can examine the “dollars for docs” section
of “ProPublica.org” that collated on its website the $761
million payments in 2009 and 2010 that have been dis-
closed by 12 companies, mostly as a result of legal settle-
ments. It is searchable by state, physician name, and
hospital. You will be surprised by the information available
there and the identity of physicians you know in your
hospitals who are receiving large sums from industry.
Dr Thomas Stossel, a professor of medicine at Harvard,
expressed the opinions of many when he said: “The use
of the word “sunshine” has an implicit aura of corrup-
tion.”12 This public reporting has been shown, in states
like Vermont, to reduce the ﬂow of money and the willing-
ness of physicians to accept payments, which in itself may
be a desirable outcome but unfortunately will also affect
innovation, research, and education.
A few details of the new Affordable Care Act (ACA)
requirements
1. Provisions from the Physician Payment Sunshine
Acts of 2007 and 2008 were included after revisions
in the Patient Protection and Affordable Care Act of
2009 (Section 6002).
2. All U.S. manufacturers with products covered by
Medicare, Medicaid, or State Children’s Health
Insurance Program must report annually to CMS,
which will post the information on a public website.
3. Required disclosures include compensation, food,
entertainment or gifts, travel, consulting fees,
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conference funding, stocks or stock options, owner-
ship or investment interest, royalties or licenses,
charitable contributions, and any other transfer of
value to a physician or a teaching hospital.
4. Disclosures will include the physician’s name,
address, national provider identiﬁer (NPI), the value,
date, form, and nature of the payment. All but the
NPI will be publicly posted.
5. Acknowledging the sensitive nature of clinical trials
and product development, payments associated
with these may be delayed for 4 years or until
approval, whichever comes ﬁrst.
6. Fines of up to $10,000 with a cap of $150,000 will
apply for each failure to report and $100,000 for
each knowing failure, not to exceed $1 million
annually.
7. CME funds were to be excluded from reporting, but
CMS proposed rules will have industry also disclose
transfers of value received by physicians for participa-
tion in CME programs.
Public comments to CMS so far have focused mostly
on the confusing guidance and some of the added rules
especially in the area of CME that complicates reporting
without adding to transparency. One thorny issue, criti-
cized by professional societies, deals with a proposed rule
of CMS, that where an organization receives a payment
or transfer of value, it will be apportioned among the physi-
cians in the organization or institution. Clearly, this would
be misleading, as the physician may not have actually
received anything, known of the transfer, or have any
ability to refuse it.
Another issue involves the ability of physicians to chal-
lenge the accuracy of reports to be on a public website. The
proposed rules allow only for a 45-day window each year
for physicians to contact the manufacturer, challenge, and
resolve the conﬂict. The lack of any mandate to provide
ongoing notiﬁcations to physicians of all transfers of value
as they occur, as well as the compressed time allowed for
challenges is expected to add a signiﬁcant burden on all
physicians to keep detailed records of all interactions with
industry throughout the year. Most professional societies
have signed onto a letter of comments asking for a resolu-
tion to the limits placed on the physician’s ability to chal-
lenge inaccurate reporting.13
The law and proposed rules are obviously very involved,
and time does not permit a prolonged discussion of all prob-
lems associated with the act. I will try to address in my last
comments the issue of education and CME. When the
Physician Payments Sunshine Act of 2008 was made part
of the ACA, speciﬁc language was deliberately removed to
speciﬁcally exclude CME payments from the reporting
requirements. The proposed CMS rules, however, re-
establish the indirect transfer of value through CME
providers as subject to reporting both to the speakers who
are independently selected by the CME providers and the
participating physicians who in general have no relationshipat all with the industrial partners providing support.14
Under that rule, the attendees here today will have to be
apportioned some of the payments made by industry to
the society to support the symposium. Since this can be an
extremely complex proposition and add an expensive
burden on the CME providers without providing any added
transparency, most societies and the Accreditation Council
for Continuing Medical Education have focused their
strongest criticisms on this proposed rule.
Speaking of added burdens, it is not clear yet how
expensive the implementation of the Sunshine Act will be.
CMS has provided estimates that have all been challenged
by the respective constituencies. On the physician side,
CMS estimates that only about 40% of physicians or
335,000 will spend an hour each reviewing the data in the
ﬁrst year at a cost of about $25 million. Professional socie-
ties have estimated, however, that a physician’s burden will
be closer to 80 hours of recordkeeping per year. CMS esti-
mates that hospitals will spend nearly a million dollars for
the same review, and the cost for manufacturers will be
about $200 million in the ﬁrst year based on half a full-
time employee for small companies and 5 to 15 full-time
employees for large companies. Industry estimates,
however, that the price tag will be far more expensive.
One of our large corporate sponsors at this meeting esti-
mated, for this address, an increase of overhead in their
medical affairs division of nearly 30%, in addition to a large
IT infrastructure investment of over $1 million. Another of
our sponsors is even more concerned about the untold cost
of lost productivity for a large number of personnel involved
in daily interaction with physicians who must now report
any possible transfer of value over $10. An independent
analysis of costs published online estimates the number of
transactions to be tracked and submitted to CMS yearly
to far exceed 105 million transactions. I cannot ﬁnd any
estimates for the additional cost to CMS in public funds
to build a database and load it in a searchable format on
a website, but it will also be in the millions. All told, esti-
mates seem to place the cost of providing transparency at
$250 to $500 million. In an environment of limited
resources and bloated health care expenditures, the money
will be spent at the expense of the bottom line of physicians,
education, and CME activities on the part of industry, and
cuts in beneﬁts on the government side.
It may be worthwhile to spend a few minutes to review
the involvement of industry in CME funding in the U.S.,
an activity that has come under signiﬁcant scrutiny lately,
with several calls to eliminate it completely. Despite oppo-
sition by the Council of Medical Specialty Societies, the
AMA delegates have adopted, in June 2011, recommenda-
tions from the Council on Ethical and Judicial Affairs that
state: “When possible, CME should be provided without
such (industry) support, or the participation of individuals
who have ﬁnancial interests in the educational subject
matter.”15 The University of Michigan no longer accepts
support of CME from industry as of January 2011. A
couple of other medical schools have followed suit. Clearly,
the impact is very different depending on the entity. The
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in-kind and volunteer work of the faculty and are very difﬁ-
cult to estimate. A substantial support from industrial part-
ners, however, remains but is diminishing over the last few
years. For UPMC, it has dropped by nearly 30% over the
last 4 years (Fig). This parallels the national trend. Total
industry support for CME has dropped by $400 million or
nearly 33% since 2007. Total funding was partially compen-
sated by additional expenditures on the part of physicians
and hospitals. The effect of the new sunshine law has not
been felt yet, but I estimate it will make matters worse.
Although universities may be able to continue some
CME offerings without industry support, this may not be
the case for societies and independent symposia. For illustra-
tion purposes, our society has a budget of $375,000 for the
annual meeting that this year, has attracted over 425 physi-
cians. Industry support contributes nearly two-thirds of the
budget with grants and exhibit charges. Without this
support, registration fees would have to be increased
threefold to an average of $1200 per physician in order to
have the SCVSmeeting, where this yearmore than 150 orig-
inal scientiﬁc contributions will be presented in various
formats. Independent symposia with a sizeable number of
invited speakers, occasionally live cases, and heavy industry
participation attract larger audiences. Although registration
at two of the busiest vascular meetings of the year average
about $1350 for practicing physicians, they still require
signiﬁcant industry support of 50% to 65% of their budget,
or an average of $2.5 million each, to provide the unique
educational experience that attracts thousands of partici-
pants. It is unlikely that society meetings and these indepen-
dent symposia would survive without industry support.
Clearly, physician attitudes are quite important in the
CME space. Most attendees, when asked about commer-
cial bias in educational activities, rarely detect it whether
the activity was supported from multiple sources, single
source, or had no support at all: 98% of all three groups re-
ported they could not discern any commercial bias in the
presentations.16 Although they may be concerned about
industry inﬂuence, only 15% of physician respondents to
a survey supported elimination of commercial support,
and less than half (42%) were willing to pay increased regis-
tration fees to decrease or eliminate such support.17
These attitudes imply that, lacking industry support,
physicians’ attendance will shrink, and some of our meet-
ings may go by the wayside. Some of them maybe should,
as there are way too many meetings as it is, but it will be
a real travesty if meetings of professional scientiﬁc societies
such as the SCVS cease to exist.
Addendum: Since this address was delivered, CMS
issued, on Feb 1, 2013, the long-awaited ﬁnal rule to imple-
ment the Physician Payments Sunshine Act. It delays the
collection of data until August 1, 2013 and excludes many
aspects of expenditures on CME education.
STUDENT MATCH DAY
Since today is Student Match Day, I would be remiss if
I completely ignore it, as this day has become an importantday on our vascular surgery academic calendar the last 5
years. As I am delivering this address, 39 medical students
are being informed that they matched into a vascular
surgery residency, while many more are being informed
there was no room for them and they will start in general
surgery. On a more personal note, my daughter is learning
where she will be spending the next 3 years of her life in an
internal medicine residency. As I shared recently in the
agonizing process that she went through to reach a decision
about the specialty she is to enter and to make her ﬁnal
rank list, I could not help but wonder about our integrated
residencies, the way we attract new talented individuals to
our workforce, and what will become of them when they
graduate. I also reminisced on how I became a vascular
surgeon and the many directions one takes in their chosen
career.
My personal tale of two cities involves Beirut and
Pittsburgh. Outside events permeate my experiences and
illustrate how randomness often dictates who we are.
I absolutely love what I do and cherish being a vascular
surgeon, but I certainly did not set out to be one.
I grew up in a small town north of Beirut, dreaming of
attending the “Ecole Polytechnique” in Paris, an advanced
engineering school. Admission was by a competitive exam
that required 2 years of preparation in Math and Physics in
France. Being 16 years old at the time and without my
parents’ permission and no ﬁnancial support, I was pushed
into applying to the American University of Beirut. To my
dismay, although French-educated until then, I was offered
admission to what was, and still is, the best university in the
Middle East. During registration in the school of Arts and
Sciences, I was asked to pick a major. I had no idea what
to pick and replied that I was only staying until I turn 18
andwould takewhatevermajor lasted only 2 years. The reply
was: only Pre-Medicine is 2 years. Two years later, I enrolled
in the School of Medicine. Fooled by randomness.
Seven years later, as a second-year resident in Surgery
at the American University of Beirut and serving an elective
rotation in Pathology at SUNY Upstate in Syracuse, I was
trying my best to move to the U.S. to escape a war-torn
country where intolerance, hatred, religious zeal, and prej-
udice ruled. I had been applying for 2 years to major
universities in the U.S., but my efforts were thwarted by
a regulation implemented 6 months before my graduation,
limiting training for international medical graduates in the
U.S. to a maximum of 3 years. I was interested then in
Pediatric Surgery, and a farewell symposium was being
organized in Pittsburgh for Dr Kieswetter, who was
retiring. Our pediatric surgeon was attending and urged
me to come to Pittsburgh, offering to share his room
with me, knowing that I was low on funds and could not
afford a hotel room. At the evening reception, Dr Bahnson
showed up as the chairman of surgery, and we shared
a lengthy conversation at the bar over a glass of wine. A
second-year resident had just been released from the
program and he offered me an interview for the 3rd year
vacant position in July of 1980. A couple of months later,
a pediatric endocrinology fellow backed out of his
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wife Silva. Fooled by randomness again.
Few years later, with the Lebanese war at its peak, the
only way to stay in the U.S. was through a waiver of the
2-year home presence requirement. Dr Bahnson stepped
in again to offer me the opportunity to join his staff and
tasked me with developing a vascular service at the
adjoining VA hospital, which was the only need of the
VA at the time. This is how I became a vascular surgeon.
Fooled by randomness one more time.
Our specialty is faced with a manpower shortage. To
detail it goes beyond the scope of my address today,
except to mention that Dr Cambria has organized a Society
for Vascular Surgery/Association of Program Directors in
Vascular Surgery task force to study means of increasing
our training positions in the U.S. to meet our pressing
needs. The fellowship programs after general surgery
have been the bedrock of our traditional recruitment
efforts, and we need to make sure we will continue to offer
training options to those, who like me, come to decide on
vascular surgery late, if not by random providence. We also
need to continue offering the traditional fellowship
programs to the incredibly large number of medical
students who have already decided on a vascular career
but are unable to match in a vascular integrated residency,
or those who, by choice, prefer to have training in both
general and vascular surgery. As unfortunately, some of
our integrated residencies are replacing rather than adding
to our training positions, new fellowships must be created
to provide every suitable and willing candidate the oppor-
tunity to share in the practice of vascular surgery that we
all enjoy. We have so far had a measure of success with
ﬁve new fellowships started this academic year and an
additional one just approved at East Carolina. I strongly
encourage members of this society who have a signiﬁcant
clinical volume but no training program yet, to join this
effort of participating in the training of our future work-
force. There are too many beneﬁts to count, including
better payments to your hospitals, better care for yourpatients, and the intellectual stimulation of younger minds
in your midst. Many resources are being developed to
assist you should you choose to embark on this venture,
and I can only assure you that there has been no more
rewarding aspect of my career than having been a program
director involved in the training of our younger
colleagues.
A few short years ago, this day in mid-March when
medical students are informed of their match selection
meant little if nothing to vascular surgeons. The new inte-
grated programs were initially welcomed with skepticism,
which has since been replaced with unbridled enthusiasm.
In the 5 years since the designation of vascular surgery as
a primary specialty, the number of programs participating
in the student match has increased from 3 to 36, while
the positions offered increased from 4 to 40. Three
more programs were just approved at the February Resi-
dency Review Committee meeting, at Case Western in
Cleveland, Albert Einstein in New York, and the Univer-
sity of Pennsylvania in Philadelphia. This 10-fold increase
has surpassed our wildest dreams, as vascular surgery has
now morphed into the most competitive match around,
surpassing orthopedics, dermatology, plastic surgery, and
others. Applicants from U.S. medical schools have been
nothing short of spectacular, and they exceed the number
of offered positions nearly three to one. This does not
include those who are interested but not offered inter-
views and do not get counted at the end of the day.
The integrated programs are also attracting to our
specialty for the ﬁrst time more women than men, allow-
ing us to tap into the skills of a larger pool of talented
physicians willing to join our ranks.
It may be too soon to congratulate ourselves, as I
unfortunately detect some residual ambivalence, mostly in
the placement of graduates of integrated residencies. The
challenge for our specialty, including all members of this
society, is to actively recruit these colleagues graduating
from an integrated program who represent the future of
vascular surgery. Most of us like to recruit colleagues in
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our specialty as well as the dramatic shift in general surgery
training toward laparoscopic procedures. Vascular surgery
today is an entirely different ﬁeld than it was a short decade
ago, and I am a ﬁrm believer the new trainees will be even
better suited for the future of our practice and nicely
complement those who will continue to follow the more
traditional pathway. This year, two residents are graduating
in June. The ﬁrst has been recruited by his home program
to stay on the faculty, and the second has opted for an
advanced aortic fellowship at the Cleveland Clinic. Next
year, 11 graduates will hit the job market and the following
year, 21. I urge you to welcome them with open arms. You
will be delighted you did.
The dedication of this specialty and this society to our
young colleagues is unparalleled and should be fostered
even more. Dr Webster concluded his presidential address
by quoting the response of J. Paul Getty to a question about
the key to success and prosperity. His answer was: “Get up
early, work hard, strike oil.” Dr Webster declared that
Vascular Surgery does not need to strike oil for success;
I think we did with our integrated training pathway!
I will leave you by introducing you to a compatriot of
mine, Nassim Taleb, a mathematician who is a master of
probability concepts, an investment manager and guru,
and a professor in both New York and Oxford. He is also
a polyglot who knows more than seven languages, and
a successful writer. His book, The Black Swan, an invest-
ment classic, was described by the Sunday Times as one
of the 12 most inﬂuential books since World War II.
Another one of his best sellers that rings a personal note
is Fooled by Randomness: The Hidden Role of Chance in
the Markets and in Life. I advise all my young colleagues
to be ready for the randomness in their life. Embrace it
and do not bemoan it. Most turns in your career can be
transformed into new opportunities. As Louis Pasteur
said in a lecture at Lille in 1854: “Chance favors only the
prepared mind.” You are prepared!
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